Tag Archives: Non Small Cell Lung Cancer Therapeutics Market

Global Non-Small Cell Lung Cancer Therapeutics Market to Reach US$15.1 bn by 2023, Asia Pacific to Report Fastest CAGR

Non-Small Cell Lung Cancer Therapeutics Market: Snapshot

Non-small cell lung cancer (NSCLC) is the one of the commonest form of lung cancers. It is the most feared too. This is because it metastasizes into the bones and other tissues, making it tough to diagnose and treat it. In fact, almost 90% of all lung cancer cases are non-small cell lung cancer. Drugs meant to treat such a type of cancer range from regular regimens to targeted therapies. They are formulated leveraging simple chemistries to advanced complex proteins. The global market for non-small cell lung cancer therapeutics has seen robust growth due to the strong awareness among people about it. Another factor majorly contributing to the market is favorable government initiatives. Further, rapid approvals for drugs for non-small cell lung cancer by regulatory bodies and generous monetary assistance for research has also filliped the market.

Despite the efficacy of targeted therapies and the uncovering of numerous molecular targets, the development of most drugs is in an early-stage pipeline. This, coupled with resistance to targeted therapies, is a major cause of worry in the non-small cell lung cancer therapeutics market.

Read Full Report: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

The global non-small cell lung cancer therapeutics market was worth US$4.9 bn in 2014. Expanding at a CAGR of 12.1% from 2015 to 2023, it is slated to achieve a value of US$15.1 bn in 2023. The global non-small cell lung cancer therapeutics market is a fragmented with robust competition among the existing players that are both generic and branded companies. Some of the prominent names operating in the market are Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Inc., AstraZeneca plc, and Novartis AG.

Burgeoning Population to Propel Market in Asia Pacific

The global market for non-small cell lung cancer therapeutics comprises five key regions: North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America leads with maximum share in market on account of the presence of a superior healthcare infrastructure and strong support by the U.S. federal government. In terms of growth rate, however, Asia Pacific is predicted to outshine all other regions owing to the burgeoning population, growing awareness about non-small cell lung cancer, increasing number of government projects pertaining to lung cancer, and ongoing efforts for timely intervention.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Effectiveness of Angiogenesis Inhibitor Drives Growth

The global market for non-small cell lung cancer therapeutics market can be segmented on the basis of drugs into EGFR inhibitor, angiogenesis inhibitor, microtubule stabilizer, kinase inhibitor, folate antimetabolites, and PD-1/PD-L1 inhibitor. At present angiogenesis inhibitor, also known as anti-angiogenics that thwart formation of new blood vessels, dominates the market. Going forward too, it is likely to retain its leading position because of the strong demand for this efficacious, targeted therapy in the crucial Europe, Japan, and the U.S. markets. Avastin, a type of angiogenesis inhibitor, is predicted to see maximum uptake. Exhibiting a CAGR of 1.8% from 2015 to 2023, the angiogenesis inhibitor segment is predicted to attain a market value of US$ 2,020.4 mn by 2023.

The folate antimetabolites segment trails the angiogenesis inhibitor segment in the global non-small cell lung cancer therapeutics market. The EGFR inhibitor and microtubule stabilizer segments come in third and fourth positions in terms of market share. The PD-1/PD-L1 inhibitor will likely outpace all other segments vis-à-vis growth in the upcoming years due to the effectiveness of the treatment, which has been corroborated by clinical data that shows double survival rate. Unveiling of new targeted therapies with more surveillance rate could, however, hobble the growth in the market.

Non-small Cell Lung Cancer Therapeutics Market: Favorable Government Policies Augmenting Demand

Genentech, a Roche company, dominates the global non-small cell lung cancer (NSCLC) therapeutics market, individually accounting for more than 36% of the market shares in 2014. Transparency Market Research finds that the market is characterized by the presence of both generic and branded companies, and positions Eli Lilly and Company as the second-most prominent player. Rest of the market is fragmented, and highly competitive, with a few formidable players including AstraZeneca plc, Celgene Corporation, Bristol-Myers Squibb, Novartis AG, Pfizer, Inc., Boehringer Ingelheim, and Sun Pharmaceutical Industries Ltd.

Rated as the most dreaded of all types of lung cancer, new NSCLC drugs are readily given approval by regulatory bodies, and research and development is encouraged. This factor is leading to rapid innovation, which will eventually decide the leader of the market in future. The global market for non-small cell lung cancer therapeutics was valued at US$4.9 bn in 2014. Rising at a robust CAGR of 12.10% during the forecast period of 2015 to 2023, the valuation is estimated to reach a US$15.1 bn mark by the end of 2023.

Read Full Report: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

Zykadia Projected for Strongest Growth Rate

The global NSCLC market has been bifurcated on the basis of drugs class, pipeline stage, and geography. By drug class, the market is categorized into angiogenesis inhibitor, epidermal growth factor receptor (EGFR) blocker, kinase inhibitor, folate antimetabolites, microtubule stabilizer, and PD-1/PD-L1 inhibitors. In 2014, the segment of angiogenesis inhibitor dominated the demand, owing to reasons such as high efficacy, targeted therapies, and increasing demand from country-wide markets of the U.S. and Japan. The report rates Zykadia, a sub-segment of kinase inhibitor, for the strongest CAGR during the forecast period, followed by Opdivo, a sub-segment of PD-1/PD-L1 inhibitors.

Geographically, the report studies the regional non-small cell lung cancer therapeutics markets in North America, Europe, Asia Pacific, and Rest of the World. North America dominated the demand in 2014 due to the presence of robust healthcare infrastructure and an efficient government system in the U.S. and Canada. However, Asia Pacific is expected to boost the demand at a stronger CAGR during the forecast period due to vast population, growing awareness about NSCLC, and increased governmental projects related to lung, cancer, and tobacco.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Wide Patient Pool Augmenting Demand

In recent past, the demand for NSCLC therapeutics has surged significantly, and has become the most common type of lung cancer. According to American lung cancer society, about two out of three people diagnosed with lung cancer are 65 years or older. According to the author of the report, “This increasing pool of patients and rising geriatric population across the globe are the primary drivers in the global market for non-small cell lung cancer therapeutics.” Additionally, the author adds that approval of some of the late-stage pipeline products, such as necitumumab and onartuzumab will further fuel the growth rate in positive direction. The report also observes that drugs used in the NSCLC treatment range from regular regimens to targeted therapies, and concurrently are based on simple chemistries to advanced complex protein. As the awareness about the prevalence of lung cancer multiplies, several governments across the globe are offering favorable policies for the players in the market. This factor is also expected to fuel the demand during the forecast period.

The information presented in this review is based on a Transparency Market Research report, titled, “Non-small Cell Lung Cancer Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.”

Non-Small Cell Lung Cancer Therapeutics Market Expected to Reach US$ 15.1 Bn in 2023

A research study, recently published by Transparency Market Research (TMR), estimates the global non-small cell lung cancer (NSCLC) therapeutics market to expand at a healthy CAGR of 12.10% over the period from 2015 to 2023 and reach a value of US$15.1 bn by the end of the forecast period.The report, titled “Non Small Cell Lung Cancer Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023,” states that the worldwide NSCLC market attained US$4.9 bn in 2014.

Of late, the demand for non-small cell lung cancer (NSCLC) therapeutics has witnessed a significant surge, globally. The robust rise in the number of patients suffering from NSCLC across the world is likely to strengthen this trend considerably in the near future. The market for NSCLC therapeutics presented a global opportunity worth US$4.9 bn in 2014. Analysts project it to rise at a CAGR of 12.10% during the period from 2015 to 2023 and attain a value of US$15.1 bn by the end of the forecast period.

Read Full Report: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

In this research report, the global NSCLC therapeutics market has been studied with a microscopic view. It aims at presenting a detailed market assessment on the basis of its past as well as current performance. The latest trends and growth opportunities within this market have been examined in-depth to determine its future status in this study.

Non-Small Cell Lung Cancer Therapeutics Market: Trends and Opportunities

Being the most common type of lung cancer, NSCLC has a large pool of patients suffering from it. Hitherto, angiogenesis inhibitor has been the most successful therapy for NSCLC. The high demand for Avastin in the U.S. and in several European countries is likely to maintain the position of angiogenesis inhibitor as the key treatment for NSCLC in the years to come.

Folate antimetabolites, EGFR inhibitors, and microtubule stabilizers are also expected to gain momentum in the global market over the next few years. In addition, the approval of late-stage pipeline products, such as necitumumab and onartuzumab, are likely to create new revenue streams for drugmakers in the near future.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Non-small Cell Lung Cancer Therapeutics Market: Geographical Analysis

On the basis of geography, the global market for NSCLC therapeutics has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. Thanks to the presence of a state-of-art healthcare infrastructure, North America has emerged as the leading contributor to this market. With favorable insurance and reimbursement scenario, researchers expect this regional market to remain dominant in the forthcoming years.

On the other hand, Asia Pacific is anticipated to offer the most promising opportunities for growth in the near future. The increasing incidence of NSCLC, coupled with unmet medical needs, is likely to make way for the adoption of NSCLC therapeutics at a higher rate. The rise in government initiatives to increase awareness regarding NSCLC among consumers in this region is also projected to propel the Asia Pacific market for NSCLC therapeutics substantially over the next few years.

Companies Mentioned in the Research Report

Owing to the presence of a large pool of players, the global market for non-small cell lung cancer therapeutics demonstrates a highly competitive and fragmented landscape. Genentech Inc., GlaxoSmithKline PLC, Pfizer Inc., Astra Zeneca PLC, Celgene Corp., Eli Lilly & Co., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the key players in this market across the world.

 

Global Demand for Non Small Cell Lung Cancer Therapeutics Market

Transparency Market Research has published a new market report titled, “Non Small Cell Lung Cancer Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.” According to the report, the global non small cell lung cancer market was valued at US$ 4.9 Bn in 2014 and is anticipated to expand at a CAGR of 12.1% from 2015 to 2023 to reach US$ 15.1 Bn in 2023.

The report provides detailed analysis of current and emerging drugs for non small cell lung cancer (NSCLC), segmenting them based on type of drug class. Drugs have been analyzed by segments such as angiogenesis inhibitor, EGFR inhibitor, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitor. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market in 2014. High demand for Avastin in major geographies such as Europe and the U.S. is likely to propel the segment during the forecast period. The angiogenesis inhibitor segment was valued at US$ 1,627.1 Mn in 2014 and is likely to account for US$ 2,020.4 Mn by 2023, expanding at a CAGR of 1.8% from 2015 to 2023.

The folate antimetabolites segment is projected to be the second highest segment of the global NSCLC therapeutics market. The EGFR inhibitor and microtubule stabilizer segments held the third and fourth largest shares of the market in terms of revenue in 2014. However, entry of new targeted therapies with more surveillance rate could restrain market growth. PD-1/PD-L1 inhibitor is likely to the fastest growing segment during the forecast period, due to affectivity of the treatment as clinical data showed double survival rate. The non-small cell lung cancer therapeutics market is anticipated to be driven by increase in incidence and diagnosis rate, government initiatives leading to rapid approval of the treatment, and development of targeted therapies

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

The report offers a detailed analysis of factors responsible for market growth and outlines a possible growth trajectory for other segments. The report is thus compiled with the primary objective of updating the stakeholders with the market dynamics, which are graphically illustrated.

AstraZeneca plc, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Novartis AG, Eli Lilly and Company, Pfizer, Inc., Genentech, Inc. (a Roche company), and Sun Pharmaceutical Industries Ltd. are the major companies operating in the global non small cell lung cancer therapeutics market. Genentech, a Roche company, was identified as the leading player in the global non-small cell lung cancer therapeutics market in 2014, accounting for a revenue share of more than 36%, followed by Eli Lilly and Company.